Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
Good morning, and welcome to Johnson & Johnson's fourth-quarter 2024 earnings conference call. (Operator Instructions) This call is being recorded. (Operator Instructions) I'd now like to turn the ...